Business Context and Reporting Period
Company: Actuate Therapeutics, Inc. (ACTU)
Filing Type: Form 8-K (Current Report)
Date of Report: June 25, 2025
Reporting Period: Event-based (June 25, 2025)
Business Overview: The Company is an emerging growth company focused on drug development, specifically the candidate elraglusib. It is currently in a pre-revenue stage with substantial doubt regarding its ability to continue as a going concern without additional capital.
Key Financial Metrics and Transaction Details
This filing details a private placement financing rather than periodic financial results. Key metrics include:
- Gross Proceeds: Approximately $4.7 million (before fees and expenses).
- Securities Issued: 666,497 shares of Common Stock and Warrants to purchase 666,497 shares.
- Purchase Price: $7.00 per share for both Common Stock and Warrants.
- Warrant Terms: Cash-only exercise; expire 20 days following the "Milestone Date."
- Milestone Date Definition: The earliest of (i) FDA Breakthrough Therapy designation for elraglusib or (ii) FDA written communication regarding registration using Phase 2 or Phase 3 data.
- Use of Proceeds: Working capital and general corporate purposes.
- Major Investor: Bios 2024 Co-Invest, LP (current stockholder) purchased 71,428 shares and warrants for $499,996. Post-closing, Bios 2024 Co-Invest, LP and affiliates will beneficially own approximately 49.9% of the Company's Common Stock.
Note: The filing text does not provide specific values for revenue, net income, operating cash flow, or total debt as of the reporting date.
Material Changes and Agreements
The Company entered into two material definitive agreements on June 25, 2025:
- Securities Purchase Agreement: Established the private placement terms described above. The transaction is expected to close on or before June 30, 2025.
- Registration Rights Agreement:
- Company must file a registration statement for resale of securities by August 9, 2025.
- Company must use reasonable efforts to make the statement effective within 90 days (if reviewed) or 5 days (if not reviewed).
- Company bears all registration fees and expenses.
- Liquidated damages provisions apply for registration failures.
Outlook, Risks, and Management Commentary
Outlook and Milestones: The Company's near-term liquidity and warrant exercise potential are tied to regulatory milestones for elraglusib, specifically Breakthrough Therapy designation or FDA guidance on registration pathways.
Risks and Contingencies:
- Going Concern: The Company explicitly states its financial condition raises substantial doubt about its ability to continue as a going concern. It requires additional capital to finance operations for fiscal year 2025.
- Development Risks: Clinical trials involve uncertain timelines and outcomes; elraglusib may not achieve positive results or regulatory approval.
- Capital Risk: Failure to obtain necessary capital could force the Company to delay, limit, or terminate development programs.
- Forward-Looking Statements: All statements regarding clinical plans and industry expectations are subject to substantial risks and uncertainties.
Investor Verification Checklist
- Verify the closing of the Private Placement on or before June 30, 2025.
- Monitor the filing of the registration statement for resale of securities by the August 9, 2025 deadline.
- Track FDA communications regarding elraglusib (Breakthrough Therapy designation or registration pathway) to determine the Warrant expiration date.
- Review the Company's cash runway post-closing to assess the "going concern" risk for the remainder of fiscal year 2025.
- Confirm the beneficial ownership percentage of Bios 2024 Co-Invest, LP post-closing (stated as ~49.9%).